

RECCE® Trademark Registered – Hong Kong

SYDNEY Australia, 2 February 2023: Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce it has been issued a trademark for RECCE® from the Trade Marks Registry Intellectual Property Department in Hong Kong.

The Company has been issued Hong Kong Trademark No. 306020153 for the RECCE® mark and has been classified under the following class(es) and specification(s):

Class 5

- Antibiotics
- Antibiotics for human use
- Pharmaceutical preparations, namely mixed antibiotic preparations

The pharmaceutical market in Hong Kong is valued at USD \$2.3 billion, with rising demand for chronic disease treatment¹. Data presented by the Hospital Authority of Hong Kong shows a proportionally high level of anti-microbial resistance in both Gram-positive and Gram-negative bacteria, such as Methicillin-resistant *Staphylococcus aureus* (MRSA), Cephalosporin-resistant and Fluoroquinolone-resistant *Escherichia coli*, in Hong Kong relative to other countries².

This newly registered trademark in Hong Kong strengthens the Company's intellectual property portfolio with those already registered in the biggest pharmaceutical markets in the world such as Australia, USA, Europe, Japan and China.

Recce Pharmaceuticals Chief Executive Officer James Graham said, "With Patents in Hong Kong for RECCE® anti-infectives in place out to 2037, we now celebrate further exclusivity through the Trademark registration of RECCE®".

This announcement has been approved for release by Recce Pharmaceuticals Board.

¹ <https://www.pacificbridgemedical.com/target-asian-markets/hong-kong-medical-market/>

² https://www.chp.gov.hk/files/pdf/amr_action_plan_eng.pdf



About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



recce.com.au
ACN 124 849 065

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

Media and Investor Relations

USA
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com